Apoptosis provoked by the oxidative stress inducer menadione (vitamin K3) is mediated by the Fas/Fas ligand system

被引:42
作者
Caricchio, R
Kovalenko, D
Kaufmann, WK
Cohen, PL
机构
[1] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Med, Chapel Hill, NC 27514 USA
[2] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Microbiol Immunol, Chapel Hill, NC 27514 USA
[3] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pathol, Chapel Hill, NC 27514 USA
[4] Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Lab Med, Chapel Hill, NC 27514 USA
关键词
menadione; Fas; apoptosis; oxidative stress; lymphocytes;
D O I
10.1006/clim.1999.4757
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Menadione, or vitamin K-3 (VK3), a potent oxidative stress inducer, has been recently used as an effective and remarkably safe cytotoxic drug for treatment of several human tumors. VK3 induces apoptotic cell death through a poorly understood mechanism. Here we show for the first time that VK3-induced apoptosis requires the Fas/FasL system. Spleen cells from both Fas- and FasL-deficient mice (C57BL/6-lpr and C57BL/ 6-gld, respectively) had much lower levels of VK, apoptosis in vitro compared to cells from control C57BL/6 mice. VK3 cytotoxicity toward mouse splenocytes was also blocked with a Fas-Fc fusion protein. VK3 induced apoptosis in Jurkat cells, coincident with an increase in both Fas and Fast expression. A Fast-resistant variant of these Jurkat cells was also resistant to VK3-induced apoptosis. Furthermore, because VK3 effects were inhibited by glutathione, a potent antioxidant, oxidative stress was linked to the Fas/FasL system. Moreover, since the Jurkat cell lines were p53 null, the activation of Fas/FasL system after oxidative stress apparently acted through a p53-independent pathway. The therapeutic relevance of the K vitamins has been growing in recent years; our findings offer new insight for improving and expanding their applications. (C) 1999 Academic Press.
引用
收藏
页码:65 / 74
页数:10
相关论文
共 53 条
[11]   Stress-induced Fas ligand expression in T cells is mediated through a MEK kinase 1-regulated response element in the Fas ligand promoter [J].
Faris, M ;
Latinis, KM ;
Kempiak, SJ ;
Koretzky, GA ;
Nel, A .
MOLECULAR AND CELLULAR BIOLOGY, 1998, 18 (09) :5414-5424
[12]   Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells [J].
Friesen, C ;
Herr, I ;
Krammer, PH ;
Debatin, KM .
NATURE MEDICINE, 1996, 2 (05) :574-577
[13]   Apoptosis induced in Jurkat cells by several agents is preceded by intracellular acidification [J].
Gottlieb, RA ;
Nordberg, J ;
Skowronski, E ;
Babior, BM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (02) :654-658
[14]   FAS LIGAND-INDUCED APOPTOSIS AS A MECHANISM OF IMMUNE PRIVILEGE [J].
GRIFFITH, TS ;
BRUNNER, T ;
FLETCHER, SM ;
GREEN, DR ;
FERGUSON, TA .
SCIENCE, 1995, 270 (5239) :1189-1192
[15]   Melanoma cell expression of Fas(Apo-1/CD95) ligand: Implications for tumor immune escape [J].
Hahne, M ;
Rimoldi, D ;
Schroter, M ;
Romero, P ;
Schreier, M ;
French, LE ;
Schneider, P ;
Bornand, T ;
Fontana, A ;
Lienard, D ;
Cerottini, JC ;
Tschopp, J .
SCIENCE, 1996, 274 (5291) :1363-1366
[16]   To die or not to die - An overview of apoptosis and its role in disease [J].
Hetts, SW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (04) :300-307
[17]   BCL-2 FUNCTIONS IN AN ANTIOXIDANT PATHWAY TO PREVENT APOPTOSIS [J].
HOCKENBERY, DM ;
OLTVAI, ZN ;
YIN, XM ;
MILLIMAN, CL ;
KORSMEYER, SJ .
CELL, 1993, 75 (02) :241-251
[18]   Requirement for the CD95 receptor-ligand pathway in c-myc-induced apoptosis [J].
Hueber, AO ;
Zornig, M ;
Lyon, D ;
Suda, T ;
Nagata, S ;
Evan, GI .
SCIENCE, 1997, 278 (5341) :1305-1309
[19]   Communication - Reactive oxygen intermediates are involved in the induction of CD95 ligand mRNA expression by cytostatic drugs in hepatoma cells [J].
Hug, H ;
Strand, S ;
Grambihler, A ;
Galle, J ;
Hack, V ;
Stremmel, W ;
Krammer, PH ;
Galle, PR .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (45) :28191-28193
[20]  
ILLERA VA, 1993, J IMMUNOL, V151, P2965